Jul 20, 2023
Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984490)....
Jun 21, 2023
Drs John M. Kane and Delbert G. Robinson discuss psychoeducation, treatment options, and possible side effects of medication for patients experiencing their first episode of schizophrenia.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984489). The...
May 23, 2023
Drs John M. Kane and Scott W. Woods discuss clinical high-risk syndrome and schizophrenia, including assessment methods, interventions, and risk indicators for future psychosis.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984484). The topics and...
Apr 19, 2023
Drs John M. Kane and Christoph U. Correll discuss the importance of ongoing assessment of psychiatric comorbidities in patients with schizophrenia and its impact on outcomes and treatment decisions.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984483)....
Mar 22, 2023
Drs John M. Kane and Jose Rubio-Lorente discuss the value of long-acting injectable formulations in reducing the risk for relapse and rehospitalization for patients diagnosed with schizophrenia.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984482). The...